Canaccord initiated coverage of Organigram with a Buy rating and C$3 price target. The firm says that despite regulatory headwinds and structural inefficiencies, the Canadian cannabis market "remains a global benchmark for legal cannabis commercialization." Organigram is accelerating its transition a vertically integrated global cannabis company, with market leading positions including the number one share in pre-rolls, concentrates and milled flower, the analyst tells investors in a research note.
